FEB 20, 2019 3:00 PM PST

Possible New Drug To Combat African Sleeping Sickness

WRITTEN BY: Nouran Amin

Scientists have teamed up to combat African sleeping sickness, which is caused by trypanosomes, unicellular protozoans transmitted by the bite of an infected tsetse fly. They specifically discovered how an inhibitory substance docks on the parasite to deactivate one of its vital proteins. "There is still a long way to go before we arrive at a pharmaceutical product," says Professor Ute Hellmich of Johannes Gutenberg University Mainz (JGU). "But our highly interdisciplinary work involving parasitology, theoretical and organic chemistry, structural biology, and biochemistry has shown how the parasite that causes sleeping sickness can be rendered harmless."

African sleeping sickness affected about 15,000 in 2014. It is challenging to differentiate the infection from malaria as they both have similar symptoms in the early stages. "Not only the poorest people in sub-Saharan Africa are threatened, but also their cattle, which are affected on a dramatic scale by certain species of Trypanosoma brucei," explained biochemist Professor Ute Hellmich.

Learn more:

As of now, only a handful of drugs seek to treat the sleeping sickness, which is fatal if untreated. However, even though new drugs are in development, the approach in the new study goes one step further: "Our inhibitor opens up the future prospect of being able to design inhibitors on a fundamental level and could thus possibly also be used in the treatment of infection with other, related pathogenic parasites, such as Leishmania," says lead author, Annika Wagner.

"We were astonished and initially thought it was a chance effect due to experimental conditions," said Hellmich. "Instead, we took a second look at the result and then discussed it with experts from different fields. Research only progresses when we work together."

Source: Johannes Gutenberg Universitaet Mainz

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUL 05, 2021
Drug Discovery & Development
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
JUL 05, 2021
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
Researchers led by New York University have found that a stimulant drug may be able to treat persistent daydreaming, fat ...
JUL 05, 2021
Neuroscience
People with Autism More Likely to Self-Medicate with Recreational Drugs
JUL 05, 2021
People with Autism More Likely to Self-Medicate with Recreational Drugs
Researchers from the University of Cambridge have found that people with autism are more likely than people without the ...
JUL 08, 2021
Genetics & Genomics
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
JUL 08, 2021
Is It Possible to Prevent Leukemia in Down Syndrome Patients?
Children with Down syndrome have a significantly higher likelihood myeloid leukemia occurring in the first five years of ...
JUL 11, 2021
Drug Discovery & Development
Could Mucus-Based Drugs Replace Antibiotics?
JUL 11, 2021
Could Mucus-Based Drugs Replace Antibiotics?
Researchers from the Copenhagen Center for Glycomics in Denmark have developed a way to produce healthy mucus artificial ...
AUG 15, 2021
Drug Discovery & Development
Diabetes Drug May Reduce Alzheimer's Risk
AUG 15, 2021
Diabetes Drug May Reduce Alzheimer's Risk
People who take a drug used to lower blood sugar levels in type 2 diabetes have less amyloid-beta in their brains, a bio ...
SEP 24, 2021
Drug Discovery & Development
WHO Recommends Antibody Treatment for High Risk COVID-19 Patients
SEP 24, 2021
WHO Recommends Antibody Treatment for High Risk COVID-19 Patients
The World Health Organization (WHO) has recommended a combination of two antibody treatments for patients at risk of adv ...
Loading Comments...